Celvivo Secures $6.6M to Propel Advanced 3D Cell Culture Platform, Appoints New CEO for Commercial Scale-Up

Dealroom News Denmark

Overview

Danish biotech Celvivo has raised $6.6 million from a mix of existing and new investors, earmarked for the accelerated commercial expansion of its ClinoStar 3D cell culture platform. This platform, which generates physiologically relevant in vitro models using microgravity-mimicking technology, addresses the urgent demand for better drug discovery tools. Jacob Philipsen has been appointed CEO to lead this strategic commercial rollout.

In Depth

Background

The pharmaceutical industry is grappling with the limitations of traditional drug discovery methods. Conventional 2D cell cultures often fail to accurately mimic in vivo conditions, leading to poor predictability and high failure rates in later development stages. Concurrently, ethical and scientific concerns surrounding animal testing have intensified the search for more robust and reliable in vitro models. This confluence has fueled a rapid surge in demand for sophisticated 3D cell culture technologies that can faithfully replicate complex biological environments, offering more dependable data for drug efficacy assessment, toxicity screening, and disease modeling. Celvivo’s ClinoStar platform directly addresses this critical industry gap, positioning itself as a vital solution for applications spanning early-stage research to preclinical evaluation.

Key Findings

Celvivo, a Danish biotechnology innovator, has successfully closed a $6.6 million funding round, drawing capital from existing investors EIFO and T&W Holding, alongside new participant VOMA Holding. This significant investment is strategically channeled to accelerate the global commercial expansion of its groundbreaking ClinoStar 3D cell culture platform. Integral to this scale-up, Jacob Philipsen has been appointed as the new CEO, tasked with spearheading the platform’s market penetration and strategic growth.

The ClinoStar platform stands out by employing unique microgravity-mimicking technology to cultivate spherical cellular aggregates—spheroids and organoids—that closely emulate in vivo tissue architecture and function. Unlike conventional 2D monolayer cultures, these advanced 3D systems deliver substantially more physiologically relevant insights into cell-cell interactions, gene expression profiles, and drug responses.

• High Physiological Relevance: Facilitates the creation of diverse 3D cell models, including tumor spheroids, organoids, and organ-on-a-chip systems, providing enhanced predictive accuracy for disease pathophysiology and drug toxicity.
• Superior Cell Yield: Optimized culture conditions enable efficient cell proliferation and the generation of stable, large quantities of 3D cell aggregates, surpassing the capabilities of conventional methodologies.
• Exceptional Reproducibility: Standardized protocols and precise environmental control minimize inter-experimental variability, ensuring consistent and reliable data acquisition crucial for robust research.
• User-Centric Design: An intuitive operating interface and streamlined workflow simplify the initiation and maintenance of 3D cell cultures, democratizing access for a broad range of researchers and technicians.

These innovations are poised to deliver substantial value across critical research domains such as oncology, regenerative medicine, and neuroscience, particularly for accelerating drug screening and unraveling complex disease mechanisms. The fresh capital infusion and new leadership are pivotal in reinforcing Celvivo’s competitive edge and accelerating the ClinoStar platform’s adoption as a standard tool in pharmaceutical and biotechnology research laboratories. The long-term vision positions ClinoStar to streamline drug discovery pipelines, reduce development costs, and ultimately expedite the delivery of safer and more effective therapies to patients, with future integration of AI and automation expected to further expand its high-throughput screening applications.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime